Kheiron Medical Technologies
Transforming cancer diagnostics through the power of deep learning.
Giving patients a better fighting chance against cancer
At Kheiron, we create Artificial Intelligence (AI) solutions that really make a difference. By helping radiologists detect cancer earlier, our next-generation technology can increase chances of survival and pave the way for less invasive treatments*. All while helping radiology departments run more efficiently and manage patient care more effectively.
*Kheiron clinical study
Read on to explore our story, beliefs and solutions. And join the AI revolution.
We’re delighted to have made the front page of The New York Times
The extensive feature details our ground-breaking work with András Vadászy and Dr. Éva Ambrózay at MaMMa Klinika in Hungary where Mia® found 13% more cancers than doctors alone: “Advancements in A.I. are beginning to deliver breakthroughs in breast cancer screening by detecting the signs that doctors miss.”
We’re doing important work with a range of pioneering organisations around the globe.
About Kheiron Medical Technologies
Learn about the people who inspire us and the challenges that drive us.
The Kheiron constellation
Our first solution: Revolutionising mammography
Mia®, whose name comes from Mammography Intelligent Assessment, is our breakthrough AI platform for breast screening. Bringing together a suite of solutions, Mia empowers radiologists and screening services to deliver confident, accurate, timely results. Ultimately, Mia supports radiologists in making the most important breast screening decision — should this woman be called back for further testing or not?
Why breast screening?
With our first solution, we chose to focus specifically on how AI could improve breast screening programmes. Why? Because early detection is directly linked to better outcomes for women.
The American Cancer Society (ACS) found that the five-year survival rate for women receiving an early-stage (localised) breast cancer diagnosis is 99%*. When diagnosis occurs at the regional stage, survivorship falls to 86% – and then again to 28% at the distant stage**.
But breast screening is only the beginning. We’re currently looking ahead at how AI can revolutionise diagnostics for other types of cancer. Watch this space.
*Living with breast cancer: Statistics on survival rates by stage
Tackling the radiology workforce crisis in the UK’s National Health Service
Across the globe, radiology departments are overworked and understaffed. The good news is, AI is already helping to solve this crisis for parts of the NHS.
Learn how, in this lively, must-watch webinar.
4th January 2023
Abstract: Post-market real-world data demonstrating use of an AI system as an extra reader to augment breast cancer detection without unnecessary recalls
Purpose To demonstrate real-world post-market benefit of artificial intelligence (AI) as an extra reader in breast cancer screening (BCS). Method A commercially available AI system…Read more
4th January 2023
Abstract: Safe and effective integration of AI as supporting reader in double reading breast cancer screening
Purpose To evaluate the effectiveness and practical implications of a novel workflow of using AI as a supporting reader for the detection of breast cancer in double reading screeni…Read more
4th January 2023
Abstract: On the importance of including unconfirmed cases when assessing the effect of AI on the recall rate in breast cancer screening
Purpose To demonstrate the importance of using representative data, including unconfirmed cases (neither positive nor negative) to assess recall rate (RR) and avoid obscuring real-…Read more
Upcoming events and conferences around the world
Case studies, blogs, and Kheiron news and opinions.
Leading the charge:
When co-founders Peter Kecskemethy and Tobias Rijken met in 2016, they started with a question: How could AI help to detect cancer sooner, and improve the lives of patients and radiologists around the world? Discover where this spark of inspiration led them.
Working together towards a better future
We have big ambitions, but we can’t achieve them alone. Learn about our partners, our clinical studies and how you can get involved.
Want to give your patients a better fighting chance against cancer? We’re eager to understand your perspective and explore how we can help you.
Contact us using the details below.